Low Level Laser Intervention for Individuals With Knee Osteoarthritis

June 21, 2021 updated by: National Cheng-Kung University Hospital

The Effects of Low Level Laser Intervention on Muscular Strength for Individuals With Knee Osteoarthritis

The purpose of this study was to investigate the intervention effects of low level laser for knee OA group

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tainan, Taiwan, 701
        • Department of Physical Therapy, National Cheng-Kung University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The severity of osteoarthritis was defined by the Kellgren-Lawrence system as grade 2 - grade 3

Exclusion Criteria:

  • Uncontrolled hypertension
  • Malignant tumor
  • Skin cancer
  • Pregnant
  • Dysesthesia
  • Pacemaker inplement
  • Cognitive problem
  • Fall record within 6 months
  • Dysfunction of blood coagulation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 808nm
The wavelength of this experimental group was 808nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
Active Comparator: 660nm
The wavelength of this experimental group was 660nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
Placebo Comparator: Control
The wavelength of control group, total power: 0.0072W, 15 minutes a session, 3 times a week for 8 weeks
The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes of muscular strength of thigh measured by handheld dynamometer
Time Frame: Baseline and after treatment, 8 weeks intervention
Muscular strength of the knee extensor and flexor on both sides and will be normalized by the body weight of participants' (lb/kg)
Baseline and after treatment, 8 weeks intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes of walking speed measured by the stop watch
Time Frame: Baseline and after treatment, 8 weeks intervention
40-m walk test, participants are instructed to walk as fast as they could, investigator records the time they spend. (seconds)
Baseline and after treatment, 8 weeks intervention
Changes of stair climbing ability measured by the stop watch
Time Frame: Baseline and after treatment, 8 weeks intervention
stair climbing test, participants are instructed to climb stairs with a total height of 180 cm as fast as they could, investigator records the time they spend. (seconds)
Baseline and after treatment, 8 weeks intervention
Changes of chair stand ability, the stop watch will be used to measure time and investigators count the time that participants complete
Time Frame: Baseline and after treatment, 8 weeks intervention
sit-to-stand test, participants are instructed to repeat chair stand movement as fast as they could, investigator records the times they complete. (times)
Baseline and after treatment, 8 weeks intervention
Changes of dynamic balance ability measured by the stop watch
Time Frame: Baseline and after treatment, 8 weeks intervention
timed UP&Go test, participants are instructed to stand up from a chair and walk as fast as they could for 3 meters and back to the chair, investigator records the time they spend. (seconds)
Baseline and after treatment, 8 weeks intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes of joint range of motion measured by the goniometer
Time Frame: Baseline and after treatment, 8 weeks intervention
Joint range of motion of the hip flexion, internal and external rotation, knee flexion, extension on both sides(degrees)
Baseline and after treatment, 8 weeks intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Cheng-Feng Lin, Ph.D, Department of Physical Therapy, National Cheng-Kung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 9, 2020

Primary Completion (Actual)

June 4, 2021

Study Completion (Actual)

June 4, 2021

Study Registration Dates

First Submitted

February 3, 2021

First Submitted That Met QC Criteria

March 31, 2021

First Posted (Actual)

April 2, 2021

Study Record Updates

Last Update Posted (Actual)

June 22, 2021

Last Update Submitted That Met QC Criteria

June 21, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • A-ER-109-187

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis, Knee

Clinical Trials on Low level laser treatment

Subscribe